Inhibikase Therapeutics, Inc. (IKT) — Financial statements
Income statement, balance sheet, and cash flow for Inhibikase Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00↓100.0% | 0.26↑111.0% | 0.12↓96.0% | 3 | |
| Cost of Revenue | 0.06↑130.3% | 0.03↓99.8% | 14↑202463.6% | 0.01↓99.9% | 11 | |
| Gross Profit | -0.06↓130.3% | -0.03↑99.8% | -13↓11544.6% | 0.12↑101.4% | -8 | |
| Operating Expenses | ||||||
| R&D Expenses | 22↑29.8% | 17↑26.4% | 14↑13.2% | 12↑6.0% | 11 | |
| General & Administrative Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 24↑107.0% | 11↑69.0% | 7↑8.4% | 6 | 0.00 | |
| Other Expenses | 0.00↑100.0% | -0.03↑99.8% | -14 | 0.00↑100.0% | -5 | |
| Operating Expenses | 46↑60.7% | 29↑324.3% | 7↓63.1% | 18↑180.4% | 7 | |
| Total Costs & Expenses | 46↑60.7% | 29↑40.5% | 20↑11.5% | 18↑2.2% | 18 | |
| Operating Results | ||||||
| Operating Income | -46↓60.7% | -29↓42.3% | -20↓10.8% | -18↓22.8% | -15 | |
| Depreciation & Amortization | 0.06↑130.3% | 0.03↓85.2% | 0.18↑2538.7% | 0.01↓100.0% | 15 | |
| EBITDA | -46↓66.9% | -27↓38.1% | -20↓10.3% | -18 | 0.00 | |
| EBIT | -46↓67.0% | -28↓37.0% | -20↓11.3% | -18↓22.3% | -15 | |
| Interest & Other Income | ||||||
| Net Interest Income | 4↑247.5% | 1↑0.8% | 1 | 0.00 | 0.00 | |
| Interest Income | 4↑247.5% | 1↑0.8% | 1↑1324.9% | 0.07↑273.7% | 0.02 | |
| Interest Expense | 0.00 | 0.00 | 0.00↓100.0% | 0.07↑273.7% | 0.02 | |
| Non-Operating Income | 0.00↑100.0% | -1 | 0.00↑100.0% | -0.07 | 0.00 | |
| Other Income / Expenses | -2↓316.1% | 1↑0.8% | 1↑1324.9% | 0.07↑473.7% | -0.02 | |
| Income Before Tax | -48↓75.4% | -28↓44.6% | -19↓5.4% | -18↓22.1% | -15 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -48↓75.4% | -28↓44.6% | -19↓5.4% | -18↓22.1% | -15 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -48↓75.4% | -28↓44.6% | -19↓5.4% | -18↓22.1% | -15 | |
| Bottom-Line Net Income | -48↓75.4% | -28↓44.6% | -19↓5.4% | -18↓22.1% | -15 | |
| EPS (Basic) | -0.49↑57.8% | -1.16↑67.5% | -3.57↑16.2% | -4.26↑12.7% | -4.88 | |
| EPS (Diluted) | -0.49↑57.8% | -1.16↑67.5% | -3.57↑16.2% | -4.26↑12.7% | -4.88 | |
| Weighted Average Shares | 98↑41.7% | 69↑1200.6% | 5↑26.9% | 4↑38.5% | 3 | |
| Weighted Average Diluted Shares | 98↑41.7% | 69↑1200.6% | 5↑26.9% | 4↑38.5% | 3 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.